Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1115
Name sarcoma
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm.
Source DiseaseOntology.org
Alt Ids DOID:3936
Path disease disease of cellular proliferation cancer cell type cancer sarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed USA 0
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Active, not recruiting USA 0
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed USA 0
NCT01010958 Phase I Valproic acid Adjuvant Valproate for High Grade Sarcomas Terminated USA 0
NCT01106872 Phase Ib/II Bevacizumab + Docetaxel + Gemcitabine + Valproic acid Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Completed USA 0
NCT01154452 Phase Ib/II Vismodegib RO4929097 + Vismodegib RO4929097 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed USA 0
NCT01189643 Phase I Bevacizumab + Irinotecan + Temozolomide Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor Active, not recruiting USA 0
NCT01294670 Phase Ib/II Etoposide + Vorinostat Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Completed USA | CAN 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | POL | ESP 0
NCT01418001 Phase Ib/II Docetaxel + Gemcitabine + Pazopanib Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed USA 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01532687 Phase II Gemcitabine Gemcitabine + Pazopanib Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Completed USA 0
NCT01593748 Phase II Docetaxel + Gemcitabine Gemcitabine + Pazopanib A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Completed USA 0
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA 0
NCT01643278 Phase I Dasatinib + Ipilimumab Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic Completed USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DNK | DEU 0
NCT01719302 Phase Ib/II Docetaxel + Gemcitabine + Pazopanib Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma Completed USA 0
NCT01719744 Phase II ENMD-2076 Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma Completed CAN 0
NCT01746238 Phase I Bevacizumab + Doxorubicin Bevacizumab/Doxorubicin/Radiation for Sarcoma Active, not recruiting USA 0
NCT01755195 Phase II Cabozantinib Cabozantinib for Adults With Advanced Soft Tissue Sarcoma Completed USA 0
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Completed USA 0
NCT01946529 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Sulfate Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Active, not recruiting USA 0
NCT01975519 Phase I Carotuximab + Pazopanib A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Completed USA 0
NCT02008877 Phase Ib/II Ganetespib + Sirolimus A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST Completed USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02049905 Phase III Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed USA | POL | NLD | ITA | ISR | HUN | FRA | ESP | DNK | CAN | AUS 2
NCT02050919 Phase II Epirubicin + Ifosfamide + Sorafenib Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Completed USA 0
NCT02066181 Phase III Sorafenib Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Completed USA | CAN 0
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02180698 Phase I GLA-SE TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02180867 Phase II Pazopanib Doxorubicin + Ifosfamide Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) Active, not recruiting USA | CAN 1
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated USA 0
NCT02267083 Phase II Camsirubicin Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma Completed USA 0
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02300545 Phase II Pazopanib Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy Completed USA 0
NCT02319824 Phase I NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy Completed USA 0
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated USA 0
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status USA 0
NCT02357810 Phase II Pazopanib + Topotecan Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Completed USA 0
NCT02359474 Phase II Trabectedin Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin (HyperTET) Active, not recruiting DEU 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting USA 0
NCT02406781 Phase II Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) Unknown status FRA 0
NCT02423863 Phase II Poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Completed USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting USA 0
NCT02451943 Phase III Olaratumab Doxorubicin A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG 5
NCT02453191 Phase Ib/II Talimogene laherparepvec TVEC and Preop Radiation for Sarcoma Completed USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02500797 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma Completed USA 0
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02558140 Phase I RG7386 A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 0
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG 9
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Completed USA 0
NCT02584647 Phase Ib/II Pexidartinib + Sirolimus Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) Active, not recruiting USA 0
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | CHE 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02630368 Phase Ib/II Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) Unknown status FRA 0
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | POL | HRV | CAN 0
NCT02636725 Phase II Axitinib + Pembrolizumab Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Completed USA 0
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Completed USA | ITA | ISR | GBR | FRA | ESP | DEU 0
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Completed USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02659020 Phase Ib/II Olaratumab Docetaxel + Gemcitabine A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Completed USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | AUS 0
NCT02783599 Phase I Doxorubicin + Olaratumab A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | ESP 0
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP | DNK 0
NCT02787642 Phase I Olaparib A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP) Completed FRA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT02795819 Phase I Pazopanib + REC-2282 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Terminated USA 0
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed USA 0
NCT02839694 Phase I Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Unknown status CAN 0
NCT02888665 Phase Ib/II Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Terminated USA | ITA | FRA | ESP | DEU | CAN 4
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Terminated USA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Active, not recruiting FRA 0
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Completed USA 0
NCT03042819 Phase I Doxorubicin + Selinexor Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas Completed CAN 0
NCT03056001 Phase II Doxorubicin + Pembrolizumab Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma Completed USA 0
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT03069378 Phase II Pembrolizumab + Talimogene laherparepvec A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Active, not recruiting USA | ITA | CAN | AUS 0
NCT03116529 Phase Ib/II Durvalumab + Tremelimumab Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS) Terminated USA 0
NCT03126591 Phase I Olaratumab + Pembrolizumab A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed USA | FRA | DNK | BEL 0
NCT03138161 Phase Ib/II Ipilimumab + Nivolumab + Trabectedin Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Recruiting USA 0
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Completed USA 0
NCT03149120 Phase II Nivolumab Nivolumab + Pazopanib Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Withdrawn USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03168061 Phase Ib/II NC-6300 Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma Unknown status USA 0
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03217266 Phase I KRT-232 MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma Active, not recruiting USA 0
NCT03242382 Phase II Palbociclib Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) Recruiting ESP 0
NCT03283696 Phase I Doxorubicin + Ifosfamide + Mesna + Olaratumab A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed USA | ITA | DEU 0
NCT03307616 Phase II Ipilimumab + Nivolumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT03338959 Phase Ib/II Pembrolizumab Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Completed USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03397186 Phase II Trabectedin Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Withdrawn USA 0
NCT03414229 Phase II Epacadostat + Pembrolizumab A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Completed USA 0
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Active, not recruiting USA 0
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Active, not recruiting USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL 2
NCT03449901 Phase II ADI-PEG 20 + Docetaxel + Gemcitabine ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Completed USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03463408 Phase I Ipilimumab + Nivolumab Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT03465592 Phase Ib/II Nivolumab Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma Recruiting USA 0
NCT03474094 Phase II Atezolizumab Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) Recruiting GBR | FRA 0
NCT03474640 Phase I Toripalimab-tpzi Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Unknown status USA 0
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Active, not recruiting USA | CAN | AUS 0
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Active, not recruiting USA | POL | GRC | ESP 2
NCT03548428 Phase II Atezolizumab Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) Recruiting FRA 0
NCT03660930 Phase Ib/II Nab-rapamycin + Pazopanib Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Patients With Nonadipocytic Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Terminated USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting USA 0
NCT03719430 Phase II Doxorubicin + Olaratumab + Sotigalimab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Active, not recruiting USA 0
NCT03727789 Phase I CBL0137 CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma Terminated USA 0
NCT03778996 Phase II Methoxsalen + Phenytoin + Sirolimus + SM88 SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) Active, not recruiting USA 0
NCT03784014 Phase III Ceritinib Dabrafenib + Trametinib Capmatinib Durvalumab + Olaparib Nilotinib Futibatinib Trametinib Palbociclib Glasdegib Lapatinib Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC) Active, not recruiting FRA 0
NCT03793361 Phase II Regorafenib Phase II Study of Regorafenib as Maintenance Therapy Active, not recruiting FRA 0
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03838744 Phase II Olaparib + Trabectedin Trabectedin Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2) Active, not recruiting ITA 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Withdrawn USA 0
NCT03886311 Phase II Nivolumab + Talimogene laherparepvec + Trabectedin Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) Recruiting USA 0
NCT03899805 Phase II Eribulin + Pembrolizumab A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03915678 Phase II Atezolizumab + BDB001 Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) Recruiting FRA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT03993678 Phase Ib/II IP-001 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. Recruiting CHE 0
NCT03994627 Expanded access Olaratumab Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma Available USA | ITA | HUN | GBR | ESP | CAN | BRA | AUT 3
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting USA 0
NCT04040205 Phase II Abemaciclib Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Recruiting USA 0
NCT04052971 Phase Ib/II ABN401 To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation Recruiting AUS 1
NCT04076579 Phase II Olaparib + Trabectedin Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Active, not recruiting USA 0
NCT04095208 Phase II Nivolumab + Relatlimab Nivolumab Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (CONGRATS) Recruiting FRA 0
NCT04095221 Phase Ib/II Irinotecan + Prexasertib + Temozolomide A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Active, not recruiting USA 0
NCT04118166 Phase II Ipilimumab + Nivolumab Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma Completed USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04145349 Phase Ib/II Cyclophosphamide + Vinorelbine Cyclophosphamide + Ramucirumab + Vinorelbine CAMFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Active, not recruiting USA | ITA | GBR | ESP | DEU | AUS 1
NCT04145622 Phase Ib/II Ifinatamab deruxtecan Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04149691 Phase I CPL304110 Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies Recruiting POL 0
NCT04165330 Phase Ib/II Anlotinib + Nivolumab Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Active, not recruiting USA 0
NCT04199026 Phase I Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Not yet recruiting USA 0
NCT04200443 Phase II Cabozantinib + Temozolomide Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04204941 Phase III Doxorubicin Doxorubicin + Tazemetostat Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Recruiting USA | GBR | CAN 1
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Active, not recruiting FRA 0
NCT04220229 Phase Ib/II Cabozantinib Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities Active, not recruiting USA 0
NCT04242238 Phase I Avelumab + Vimseltinib Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Active, not recruiting USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04332874 Phase II Pembrolizumab A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Recruiting USA 0
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04441099 Phase Ib/II NBE-002 NBE-002 in Patients With Advanced Solid Tumors Terminated USA 0
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Active, not recruiting USA | GBR 0
NCT04480502 Phase II Envafolimab + Ipilimumab Envafolimab ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC) Active, not recruiting USA | GBR 0
NCT04535713 Phase II Docetaxel + Doxorubicin + Gemcitabine + Nivolumab Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Recruiting USA 0
NCT04551430 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04577014 Phase Ib/II Docetaxel + Gemcitabine + Retifanlimab INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04593758 Phase Ib/II CPI-613 + Hydroxychloroquine To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue Completed USA 0
NCT04595747 Phase II Rogaratinib Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Active, not recruiting USA 0
NCT04595994 Phase I Selinexor Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Recruiting ESP 0
NCT04599062 Phase Ib/II Talimogene laherparepvec TVEC and Preop Radiation for Sarcoma (8 ml Dose) Active, not recruiting USA 0
NCT04648826 Phase Ib/II Azacitidine + Bintrafusp alfa Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies Withdrawn USA 0
NCT04650984 Phase III Doxorubicin + Onfekafusp alfa Doxorubicin A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC) Recruiting POL | ITA | FRA | ESP | DEU 0
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting FRA 0
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Suspended USA 0
NCT04718675 Phase I KB-0742 A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma Recruiting USA | GBR | ESP 0
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04733183 Phase II Dacarbazine Dacarbazine + Onfekafusp alfa Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma (FLASH) Recruiting POL | ITA | FRA | ESP | DEU 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04811196 Phase I Selinexor A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients Active, not recruiting CAN 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04874311 Phase II Bintrafusp alfa + Doxorubicin Doxorubicin Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) Recruiting FRA 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT04995003 Phase I HER2 CAR-T cells + Nivolumab Cyclophosphamide + Fludarabine + HER2 CAR-T cells + Pembrolizumab HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Recruiting USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05043649 Phase I Camsirubicin + Pegfilgrastim Camsirubicin + Pegfilgrastim to Determine MTD in ASTS Terminated USA 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05094804 Phase Ib/II Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Recruiting USA 0
NCT05100628 Phase I NOX66 Doxorubicin + NOX66 A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma Terminated USA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05114668 Phase I EVT801 Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours Active, not recruiting FRA 0
NCT05116254 Phase I AZD1390 + Durvalumab AZD1390 Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1) Recruiting NLD 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05180695 Phase Ib/II Pazopanib + Siremadlin HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC) Recruiting FRA 0
NCT05229601 Phase I HFB301001 A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Active, not recruiting USA | ESP 0
NCT05238883 Phase I HFB200301 HFB200301 + Tislelizumab A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Completed USA | ESP | BEL | ARG 2
NCT05333458 Phase II Atezolizumab + Selinexor Atezolizumab Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma Recruiting USA 0
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05448820 Phase Ib/II Envafolimab + YH001 Doxorubicin + Envafolimab + YH001 YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma Active, not recruiting USA 0
NCT05488366 Phase I Pembrolizumab Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma Recruiting USA 0
NCT05515575 Phase II Niraparib A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA Active, not recruiting USA 0
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Completed USA 1
NCT05580588 Phase II SPH4336 Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Recruiting USA 0
NCT05621668 Phase I AttIL12 T-cells + Cyclophosphamide A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Recruiting USA 0
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS | ARG 2
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05655598 Phase I Palbociclib + Pimitespib TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Withdrawn USA 0
NCT05688280 Phase Ib/II IP-001 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) Recruiting USA | GBR | FRA | DEU | CHE 0
NCT05691491 Phase Ib/II M1774 + Temozolomide Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Recruiting USA 0
NCT05711615 Phase I Pegylated liposomal doxorubicin + Peposertib Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05755113 Phase II Tigilanol tiglate A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma Recruiting USA 0
NCT05809830 Phase Ib/II Doxorubicin Doxorubicin + LB-100 Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) Recruiting ESP 0
NCT05813327 Phase Ib/II ADI-PEG 20 + Ifosfamide + Mesna Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma Recruiting USA 0
NCT05836571 Phase II Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Recruiting USA | CAN 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0
NCT06047977 Phase I Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors Not yet recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06084689 Phase II BI 907828 + Ezabenlimab Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) Not yet recruiting FRA 0
NCT06090266 Phase Ib/II Cemiplimab + OR502 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Recruiting USA 0
NCT06092580 Phase I AWT020 Phase 1 Study of AWT020 in Advanced Cancer Recruiting AUS 0
NCT06128863 Phase II Eftilagimod alpha + Pembrolizumab Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO) Recruiting POL 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06217536 Phase Ib/II Lurbinectedin Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Not yet recruiting 0
NCT06239272 Phase Ib/II Selinexor Pazopanib Doxorubicin + Ifosfamide NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA | AUS 0
NCT06274437 Phase I BND-35 + Cetuximab BND-35 + Nivolumab BND-35 A Study of BND-35 in Participants With Advanced Solid Tumors Recruiting ISR 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06290388 Phase Ib/II 23ME-01473 Study of 23ME-01473 in Patients With Advanced Solid Malignancies Recruiting USA 0
NCT06308419 Phase I Gemcitabine + Nab-rapamycin A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions Recruiting USA 0
NCT06332274 Phase III Tislelizumab tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) Not yet recruiting FRA 0
NCT06333314 Phase II Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) Recruiting FRA 0
NCT06416436 Phase I Atezolizumab Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients Not yet recruiting USA 0
NCT06422806 Phase III Doxorubicin Doxorubicin + Pembrolizumab Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Recruiting USA 0
NCT06444815 Phase I VET3-TGI Pembrolizumab + VET3-TGI A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) Recruiting USA 0
NCT06474676 Phase I AttIL12 T-cells Cyclophosphamide T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. Not yet recruiting USA 0
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06630325 Phase II Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Not yet recruiting USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0
NCT06641908 Phase I M3554 Anti-GD2 ADC M3554 in Advanced Solid Tumors Not yet recruiting USA | FRA | BEL 1
NCT06660810 Phase I Talimogene laherparepvec Neoadjuvant Intralesional Injection of Talimogene Laherparepvec Not yet recruiting USA 0